Beddow Capital Management Inc. Sells 21,290 Shares of Pfizer (PFE)

Beddow Capital Management Inc. trimmed its stake in shares of Pfizer (NYSE:PFE) by 7.2% during the 4th quarter, HoldingsChannel reports. The firm owned 275,965 shares of the biopharmaceutical company’s stock after selling 21,290 shares during the quarter. Pfizer makes up 4.1% of Beddow Capital Management Inc.’s investment portfolio, making the stock its 8th largest position. Beddow Capital Management Inc.’s holdings in Pfizer were worth $9,995,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of PFE. BlackRock Inc. lifted its holdings in Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after purchasing an additional 12,183,218 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Pfizer by 11.9% in the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock valued at $2,562,162,000 after buying an additional 7,534,957 shares during the last quarter. Stifel Financial Corp raised its position in shares of Pfizer by 5,413.5% in the third quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock valued at $262,515,000 after buying an additional 7,226,697 shares during the last quarter. American Century Companies Inc. raised its position in shares of Pfizer by 46.6% in the fourth quarter. American Century Companies Inc. now owns 22,539,888 shares of the biopharmaceutical company’s stock valued at $816,395,000 after buying an additional 7,161,892 shares during the last quarter. Finally, Boston Partners raised its position in shares of Pfizer by 18.4% in the third quarter. Boston Partners now owns 27,741,320 shares of the biopharmaceutical company’s stock valued at $990,365,000 after buying an additional 4,314,466 shares during the last quarter. 71.65% of the stock is currently owned by institutional investors and hedge funds.

In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares in the company, valued at $1,374,505.21. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Ian C. Read sold 132,312 shares of Pfizer stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total transaction of $4,764,555.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 380,349 shares of company stock valued at $13,829,340. 0.06% of the stock is owned by company insiders.

A number of brokerages have recently commented on PFE. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. SunTrust Banks reiterated a “hold” rating and issued a $40.00 target price (up from $33.00) on shares of Pfizer in a research report on Monday, January 29th. UBS set a $42.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Morgan Stanley increased their target price on shares of Pfizer from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $40.08.

Pfizer opened at $35.71 on Friday, MarketBeat Ratings reports. Pfizer has a 12-month low of $35.64 and a 12-month high of $35.80. The stock has a market cap of $212.46 billion, a P/E ratio of 13.48, a PEG ratio of 1.77 and a beta of 0.89. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The firm had revenue of $12.91 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same period last year, the business earned $0.69 earnings per share. Pfizer’s revenue was up 1.0% compared to the same quarter last year. equities research analysts predict that Pfizer will post 2.95 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s payout ratio is currently 51.32%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply